Pratosartan
Alternative Names: DA 727; KD 3671; KT 3671Latest Information Update: 12 May 2015
At a glance
- Originator Kotobuki Seiyaku
 - Developer Boryung Pharmaceutical; Daiichi Sankyo Company; Kotobuki Pharmaceutical
 - Class Antihypertensives; Imidazoles; Small molecules; Tetrazoles
 - Mechanism of Action Angiotensin type 1 receptor antagonists
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- No development reported Hypertension
 - Discontinued Atherosclerosis; Diabetic nephropathies; Glomerulonephritis
 
Most Recent Events
- 13 Apr 2012 Pratosartan is still in phase III development in South Korea and phase II in Japan for Hypertension
 - 10 Sep 2010 Clinical development is ongoing in Japan and South Korea
 - 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc